Can I Take St. John's Wort with Low-Dose Naltrexone?

What Is Low-Dose Naltrexone and Why Is the Dose So Important?

Low-Dose Naltrexone (LDN) uses the same molecule as full-dose naltrexone (50 mg, FDA-approved for opioid and alcohol use disorder) but at doses roughly 1/10th to 1/30th of that range. Typical LDN protocols target 1.5 mg to 4.5 mg taken orally at bedtime. At this narrow dose window, naltrexone is thought to produce a brief, transient blockade of opioid receptors, which triggers a rebound increase in endogenous opioid tone overnight and simultaneously modulates toll-like receptor 4 (TLR4) signaling on glial cells.

Why the Narrow Dose Window Matters

The proposed anti-inflammatory mechanism of LDN depends entirely on achieving a specific, low plasma concentration. If plasma levels fall too far below the target range, the brief receptor blockade never occurs and no rebound upregulation follows. If levels rise toward the full-dose range, the pharmacology shifts toward sustained opioid antagonism, losing the pulsatile effect that researchers hypothesize drives LDN's benefit.

A 2013 crossover pharmacokinetic study in healthy volunteers found that oral naltrexone 50 mg achieved a mean peak plasma concentration (Cmax) of roughly 8.4 ng/mL, with the active metabolite 6-beta-naltrexol reaching approximately 46 ng/mL [1]. Scaling linearly to a 4.5 mg LDN dose predicts a Cmax near 0.75 ng/mL for naltrexone, leaving very little pharmacokinetic buffer before therapeutic effect is lost. Any inducer that reduces this already-small AUC represents a meaningful clinical problem.

The Metabolic Pathway of Naltrexone

Naltrexone is primarily reduced by carbonyl reductase to 6-beta-naltrexol, but cytochrome P450 enzymes, especially CYP3A4, handle a secondary oxidative pathway and also govern intestinal first-pass extraction [2]. P-glycoprotein (P-gp, encoded by ABCB1) acts as an efflux transporter in the gut wall, pumping naltrexone back into the intestinal lumen and limiting oral bioavailability. Both CYP3A4 and P-gp are inducible by St. John's Wort's primary active constituent, hyperforin.

How St. John's Wort Affects Drug Metabolism

St. John's Wort (Hypericum perforatum) is one of the most widely used herbal supplements in the United States, with approximately 17% of adults reporting regular use in national survey data [3]. It is sold for mild-to-moderate depression and mood support, often as a 300 mg tablet standardized to 0.3% hypericin three times daily.

The Hyperforin-PXR-CYP3A4 Mechanism

The interaction concern is driven almost entirely by hyperforin, not hypericin. Hyperforin binds the pregnane X receptor (PXR), a nuclear receptor that acts as a master regulator of drug-metabolizing enzymes. PXR activation by hyperforin upregulates transcription of CYP3A4, CYP2C9, and the ABCB1 gene that encodes P-gp [4]. The FDA's 2020 Drug Interaction Studies Guidance classifies St. John's Wort as a "strong CYP3A4 inducer" based on clinical midazolam AUC data showing reductions exceeding 80% [5].

To put that in concrete terms: in a 2000 landmark study published in The Lancet, Piscitelli et al. (N=8) showed that St. John's Wort reduced indinavir (a CYP3A4 substrate) plasma AUC by 57% over 14 days of co-administration [6]. The magnitude of induction varies by substrate, but any CYP3A4-processed drug with a narrow therapeutic window is at risk of sub-therapeutic exposure.

Time Course of Induction and Washout

CYP3A4 induction by St. John's Wort is not immediate. Enzyme upregulation begins within 3 to 5 days of continuous dosing and reaches maximum effect at roughly 7 to 14 days [4]. After stopping the supplement, CYP3A4 activity returns to baseline in approximately 14 days as the newly synthesized enzyme protein turns over. This means a patient who stops St. John's Wort the same day they start LDN may still experience reduced naltrexone exposure for two additional weeks.

Products Labeled "Low Hyperforin" and Whether They Are Safer

Some newer St. John's Wort formulations deliberately minimize hyperforin content to reduce drug interactions while preserving antidepressant activity (which some researchers attribute more to inhibition of serotonin and norepinephrine reuptake). One example is the Ze 117 extract studied in a 2000 RCT by Woelk (N=324) [7]. These low-hyperforin products may produce less CYP3A4 induction, but published pharmacokinetic data confirming a safe interaction profile with naltrexone specifically do not exist. Clinicians should not assume safety based on the label alone.

The Direct Interaction: What Happens to LDN Plasma Levels?

No published pharmacokinetic trial has studied the combination of St. John's Wort and low-dose naltrexone specifically. This is a meaningful evidence gap. The interaction is inferred from: (1) naltrexone's established CYP3A4 and P-gp metabolism, (2) St. John's Wort's well-characterized induction of both pathways, and (3) analogy to documented interactions between St. John's Wort and other low-bioavailability opioid-class compounds.

Predicting Magnitude: A Pharmacokinetic Reasoning Framework

Oral naltrexone has approximately 5% to 40% absolute bioavailability due to extensive hepatic first-pass metabolism, with the wide range reflecting inter-individual variability in CYP3A4 activity and P-gp expression [2]. When both intestinal P-gp and hepatic CYP3A4 are simultaneously induced, the expected effect is multiplicative, not additive. A moderate CYP3A4 induction alone might reduce AUC by 30 to 50%; adding P-gp induction at the gut wall can push total AUC reduction higher. For a drug already operating at 1/10th of a clinically established dose, a 30 to 50% AUC reduction could plausibly render LDN sub-therapeutic.

Pharmacodynamic Interactions: Are There Any?

The interaction is primarily pharmacokinetic. There is no known direct pharmacodynamic antagonism between St. John's Wort and naltrexone at the opioid receptor or TLR4 level. St. John's Wort does inhibit serotonin, dopamine, and norepinephrine reuptake, but LDN does not substantially affect these pathways at therapeutic doses. The concern is almost entirely about plasma exposure, not receptor-level competition.

What This Means for Fibromyalgia and Autoimmune Patients

LDN's off-label evidence base is modest but growing. A 2013 pilot RCT by Younger et al. (N=31) found that LDN 4.5 mg reduced fibromyalgia symptom severity by 30% compared with 2% for placebo (P<0.001) [8]. A 2023 systematic review in the Journal of Autoimmunity identified 15 clinical trials across Crohn's disease, multiple sclerosis, and fibromyalgia with broadly positive signals, though most trials were small [9]. Patients pursuing LDN for these indications often have limited pharmacological alternatives, making preservation of LDN's plasma exposure clinically meaningful. Losing even a fraction of that narrow therapeutic window is a real setback.

Clinical Guidance: What Should You Actually Do?

If You Are Currently Taking Both

Do not stop either medication abruptly without talking to your prescribing clinician first. Stopping St. John's Wort suddenly after a period of CYP3A4 induction does not immediately restore LDN levels; there is a 14-day transition during which enzyme activity normalizes. If your clinician agrees that stopping St. John's Wort is appropriate, plan a washout of at least 14 days before expecting LDN to reach its intended plasma range.

During that transition window, your clinician may want to track symptom scores or, in some cases, obtain a plasma naltrexone or 6-beta-naltrexol level (available through reference labs such as Quest Diagnostics) to confirm adequate exposure after the induction resolves.

If You Are Considering Starting St. John's Wort While on LDN

The short answer: discuss it first. Depression and mood disorders are common comorbidities in patients with fibromyalgia and autoimmune conditions, and the appeal of an over-the-counter supplement is understandable. However, evidence-based alternatives with less interaction potential exist, including cognitive-behavioral therapy and, if medication is needed, SSRIs with lower CYP3A4 burden (though SSRIs carry their own interaction considerations with LDN that require clinician review).

If your clinician does decide that St. John's Wort is appropriate, using a low-hyperforin extract at the lowest effective dose and monitoring LDN efficacy clinically over 30 to 60 days is a more cautious path than standard high-hyperforin products.

If You Are Starting LDN and Already Take St. John's Wort

Your prescribing clinician should know about the St. John's Wort before your LDN dose is finalized. Some clinicians may choose a slightly higher starting LDN dose (still within the 1.5 to 4.5 mg range) and monitor closely. Others may recommend tapering off St. John's Wort first, waiting the 14-day washout, then initiating LDN. There is no published protocol for this scenario; clinical judgment guides the decision.

Monitoring, Red Flags, and When to Contact Your Clinician

Signs That LDN May Not Be Working as Expected

Patients on LDN for fibromyalgia typically expect to see at least partial symptom improvement within 8 to 12 weeks of reaching their target dose. Absence of any response could reflect inadequate plasma exposure from CYP3A4 induction rather than true LDN non-response. The distinction matters because true non-response might prompt discontinuation, while pharmacokinetic failure is correctable.

Red flags that warrant a prompt call to your clinician include:

• Complete absence of any clinical change after 8 to 12 weeks at target dose
• New or worsening symptoms that coincide with starting or increasing St. John's Wort dose
• Any plan to add, change, or stop either agent without first checking for interactions

Lab Monitoring Options

Routine plasma naltrexone assays are not standard practice for LDN patients, but they are technically available. The primary endpoint in clinical monitoring is symptom response. If a patient and clinician suspect pharmacokinetic failure due to a known inducer, a single plasma draw timed at 1 to 2 hours after an LDN dose (approximate Tmax) can provide directional information. Reference ranges for LDN are not formally established, but a Cmax below 0.3 ng/mL at a 4.5 mg dose would suggest substantial first-pass induction.

Drug Interaction Screening Resources for Patients

Two freely accessible interaction checkers that include herbal products are the Natural Medicines database (naturalmedicines.therapeuticresearch.com, subscription required but often available through public libraries) and the NIH National Center for Complementary and Integrative Health's herb-drug interaction resources at nccih.nih.gov [10]. Running any new supplement through these tools before adding it to an existing medication list is a reasonable habit.

What the Guidelines Say

The FDA's 2020 "In Vitro Drug Interaction Studies" guidance document explicitly lists St. John's Wort as a positive control strong CYP3A4 inducer, meaning it is used as the reference benchmark against which new drugs' interaction potential is measured [5]. This is a regulatory statement of the supplement's potency as an inducer.

The American Herbal Products Association and Natural Medicines Comprehensive Database both rate the St. John's Wort interaction with CYP3A4 substrates as "major" for compounds with narrow therapeutic windows [10]. Naltrexone at low doses qualifies as a narrow-window drug in clinical practice, even though it lacks an FDA-defined "narrow therapeutic index" designation (which is reserved for drugs like warfarin and lithium where toxicity is the concern; here the concern is loss of efficacy).

"Hyperforin is one of the most potent known inducers of intestinal and hepatic CYP3A4 in humans, with clinical AUC reductions comparable to rifampin in some substrates," according to a 2003 review by Moore et al. In the Journal of Pharmacology and Experimental Therapeutics [11]. Rifampin is the gold standard for strong CYP3A4 induction in drug development studies, and placing St. John's Wort in that category signals a serious pharmacokinetic interaction risk.

Special Populations and Considerations

Patients on Immunosuppressants or Other CYP3A4 Substrates

Many patients using LDN off-label for autoimmune conditions are also on immunosuppressive drugs including cyclosporine, tacrolimus, or mycophenolate. St. John's Wort has documented, clinically serious interactions with each of these agents. A 2000 case series by Ruschitzka et al. Reported acute heart transplant rejection in two patients after they self-initiated St. John's Wort, attributed to cyclosporine AUC reductions of up to 46% [12]. Adding St. John's Wort to a regimen that already includes an immunosuppressant and LDN compounds the interaction risk.

Compounded vs. Commercially Manufactured Naltrexone

LDN is almost always obtained through compounding pharmacies because no FDA-approved naltrexone product exists at doses below 50 mg. Compounded products may use different fillers and release characteristics than the 50 mg Vivitrol or Revia formulations used in published pharmacokinetic studies. Extended-release compounded LDN capsules, for example, may rely more heavily on dissolution through the intestinal wall over a longer time period, making them potentially more vulnerable to P-gp induction (which acts at the gut epithelium) than an immediate-release preparation.

Pregnancy and Breastfeeding

Both LDN and St. John's Wort have limited safety data in pregnancy and lactation. LDN is a category C drug (risk not ruled out). St. John's Wort is rated "likely unsafe" in pregnancy by Natural Medicines due to possible uterotonic effects [10]. Combining both in a pregnant or breastfeeding patient is not appropriate, and the question of whether to continue either agent at all requires obstetric and specialist consultation.